Brief: Pacira Biosciences Receives FDA 510K Clearance For New Iovera° Smarttip To Manage Chronic Low Back Pain Via Long-Lasting Medial Branch Nerve Block
07/01/2025 13:06
Jan 7 (Reuters) - Pacira Biosciences Inc PCRX.O :
* PACIRA BIOSCIENCES RECEIVES FDA 510K CLEARANCE FOR NEW
IOVERA°
SMARTTIP TO MANAGE CHRONIC LOW BACK PAIN VIA LONG-LASTING MEDIAL
BRANCH NERVE BLOCK
Source text: ID:nGNXllxzg
Further company coverage: PCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pacira Biosciences
See all newsBrief: Pacira Biosciences Inc - Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "For" All Of Pacira's Director Nominees
Brief: Pacira Biosciences Urges Stockholders To Vote "For" Election Of Pacira's Nominees On Blue Proxy Card
Brief: Doma Perpetual Urges Pacira Biosciences Shareholders To Judge Sale Price Adequacy
Brief: Doma Perpetual Capital Management Calls For Removal Of Pacira CEO And Strategic Sale
Brief: Pacira Biosciences Sends Letter To Stockholders Reiterating Superior Qualifications Of Its Board Nominees